A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with adult-type diffuse glioma with an IDH1/2 mutation (INDIGO): Updated efficacy results Meeting Abstract
| Authors: | Mellinghoff, I. K.; van den Bent, M. J.; Touat, M.; Blumenthal, D. T.; Peters, K. B.; Ellingson, B. M.; Clarke, J. L.; Mendez, J.; Yust-Katz, S.; Mason, W. P.; Ducray, F.; Umemura, Y.; Nabors, B.; Hottinger, A. F.; Arakawa, Y.; Sepulveda, J. M.; Wick, W.; Soffietti, R.; Perry, J. R.; Giglio, P.; de la Fuente, M.; Maher, E. A.; Tron, A. E.; Zhao, D.; Pandya, S. S.; Steelman, L.; Hassan, I.; Wen, P. Y.; Cloughesy, T. F. |
| Abstract Title: | A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with adult-type diffuse glioma with an IDH1/2 mutation (INDIGO): Updated efficacy results |
| Meeting Title: | 29th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) |
| Journal Title: | Neuro-Oncology |
| Volume: | 26 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2024 Nov 21-24 |
| Meeting Location: | Houston, TX |
| ISSN: | 1522-8517 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-11-01 |
| Start Page: | viii108 |
| End Page: | viii109 |
| Language: | English |
| ACCESSION: | WOS:001362580000028 |
| DOI: | 10.1093/neuonc/noae165.0420 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: CTNI-53 (Citation ID: NOAE165.0420) -- Source: Wos |
